104 related articles for article (PubMed ID: 15838323)
1. Endothelin-1 and cardiac function in anthracycline-treated patients: a 1-year follow-up.
Zsáry A; Szücs S; Keltai K; Pásztor E; Schneider T; Rosta A; Sármán P; Jánoskuti L; Fenyvesi T; Karádi I
J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S372-5. PubMed ID: 15838323
[TBL] [Abstract][Full Text] [Related]
2. Role of endothelin-1 in the development of a special type of cardiomyopathy.
Zsáry A; Szücs S; Schneider T; Rosta A; Sármán P; Fenyvesi T; Karádi I
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():272S-275S. PubMed ID: 12193102
[TBL] [Abstract][Full Text] [Related]
3. Endothelins: a possible mechanism of cytostatics-induced cardiomyopathy.
Zsáry A; Szûcs S; Keltai K; Schneider T; Rosta A; Sármán P; Fenyvesi T; Karádi I
Leuk Lymphoma; 2004 Feb; 45(2):351-5. PubMed ID: 15101723
[TBL] [Abstract][Full Text] [Related]
4. [Late cardiotoxicity in patients with malignant lymphoma treated with doxorubicin chemotherapy].
Elbl L; Vásová I; Navrátil M; Tomásková I; Jedlicka F; Chaloupka V; Vorlícek J
Vnitr Lek; 2006 Apr; 52(4):328-38. PubMed ID: 16755989
[TBL] [Abstract][Full Text] [Related]
5. [Effect of high-dose chemotherapy with subsequent transplantation of blood-forming cells on left ventricle function in patients with malignant lymphomas treated with doxorubicin in primary chemotherapy].
Elbl L; Vásová I; Krejcí M; Navrátil M; Tomásková I; Jedlicka F; Chaloupka V; Mayer J; Vorlícek J
Vnitr Lek; 2006 Mar; 52(3):221-31. PubMed ID: 16722153
[TBL] [Abstract][Full Text] [Related]
6. Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens.
Paoli D; Rizzo F; Fiore G; Pallotti F; Pulsoni A; Annechini G; Lombardo F; Lenzi A; Gandini L
Hum Reprod; 2016 Feb; 31(2):263-72. PubMed ID: 26705149
[TBL] [Abstract][Full Text] [Related]
7. Radionuclide ventriculography detects early anthracycline cardiotoxicity in children with Hodgkin lymphoma.
Tantawy AA; Elmasry OA; Shaaban M; Toaima DN; El Shahat AM
J Pediatr Hematol Oncol; 2011 May; 33(4):e132-7. PubMed ID: 21516011
[TBL] [Abstract][Full Text] [Related]
8. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
Engert A; Diehl V; Franklin J; Lohri A; Dörken B; Ludwig WD; Koch P; Hänel M; Pfreundschuh M; Wilhelm M; Trümper L; Aulitzky WE; Bentz M; Rummel M; Sezer O; Müller-Hermelink HK; Hasenclever D; Löffler M
J Clin Oncol; 2009 Sep; 27(27):4548-54. PubMed ID: 19704068
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of cardiac function in patients with Hodgkin's disease treated with mediastinal irradiation and combination chemotherapy including doxorubicin.
LaMonte CS; Yeh SD; Straus DJ
Cancer Treat Rep; 1986 Apr; 70(4):439-44. PubMed ID: 2421892
[TBL] [Abstract][Full Text] [Related]
10. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
Eich HT; Diehl V; Görgen H; Pabst T; Markova J; Debus J; Ho A; Dörken B; Rank A; Grosu AL; Wiegel T; Karstens JH; Greil R; Willich N; Schmidberger H; Döhner H; Borchmann P; Müller-Hermelink HK; Müller RP; Engert A
J Clin Oncol; 2010 Sep; 28(27):4199-206. PubMed ID: 20713848
[TBL] [Abstract][Full Text] [Related]
11. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V
J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577
[TBL] [Abstract][Full Text] [Related]
12. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.
Diehl V; Franklin J; Hasenclever D; Tesch H; Pfreundschuh M; Lathan B; Paulus U; Sieber M; Rueffer JU; Sextro M; Engert A; Wolf J; Hermann R; Holmer L; Stappert-Jahn U; Winnerlein-Trump E; Wulf G; Krause S; Glunz A; von Kalle K; Bischoff H; Haedicke C; Duehmke E; Georgii A; Loeffler M
J Clin Oncol; 1998 Dec; 16(12):3810-21. PubMed ID: 9850026
[TBL] [Abstract][Full Text] [Related]
13. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients.
Nousiainen T; Jantunen E; Vanninen E; Hartikainen J
Br J Cancer; 2002 Jun; 86(11):1697-700. PubMed ID: 12087452
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of acute and early cardiotoxicity in survivors of Hodgkin's disease treated with ABVD or BEACOPP regimens.
Elbl L; Vasova I; Kral Z; Tomaskova I; Smardova L; Wagnerova B; Jedlicka F; Vorlicek J
J Chemother; 2006 Apr; 18(2):199-208. PubMed ID: 16736890
[TBL] [Abstract][Full Text] [Related]
15. Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial.
Carde P; Karrasch M; Fortpied C; Brice P; Khaled H; Casasnovas O; Caillot D; Gaillard I; Bologna S; Ferme C; Lugtenburg PJ; Morschhauser F; Aurer I; Coiffier B; Meyer R; Seftel M; Wolf M; Glimelius B; Sureda A; Mounier N
J Clin Oncol; 2016 Jun; 34(17):2028-36. PubMed ID: 27114593
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy for Hodgkin's disease.
Ekert H
N Engl J Med; 2003 Sep; 349(12):1186-7; author reply 1186-7. PubMed ID: 13679536
[No Abstract] [Full Text] [Related]
17. Cardiopulmonary response to exercise in patients with different degrees of lung toxicity after radio-chemotherapy for Hodgkin's disease.
Villani F; Busia A; Villani M; Laffranchi A; Viviani S; Bonfante V
Anticancer Res; 2009 Feb; 29(2):777-83. PubMed ID: 19331235
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of survival in Hodgkin's lymphoma.
Canellos GP; Niedzwiecki D; Johnson JL
N Engl J Med; 2009 Dec; 361(24):2390-1. PubMed ID: 20007568
[No Abstract] [Full Text] [Related]
19. Follow-up of sperm concentration and motility in patients with lymphoma.
Tal R; Botchan A; Hauser R; Yogev L; Paz G; Yavetz H
Hum Reprod; 2000 Sep; 15(9):1985-8. PubMed ID: 10967000
[TBL] [Abstract][Full Text] [Related]
20. Pre-existing arterial hypertension as a risk factor for early left ventricular systolic dysfunction following (R)-CHOP chemotherapy in patients with lymphoma.
Szmit S; Jurczak W; Zaucha JM; Drozd-Sokołowska J; Spychałowicz W; Joks M; Długosz-Danecka M; Torbicki A
J Am Soc Hypertens; 2014 Nov; 8(11):791-9. PubMed ID: 25455004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
